207 related articles for article (PubMed ID: 35074582)
1. Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis.
Hu N; Shen D; Yang X; Cui L; Liu M
J Clin Neurosci; 2022 Mar; 97():93-98. PubMed ID: 35074582
[TBL] [Abstract][Full Text] [Related]
2. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.
Hu N; Shen D; Yang X; Cui L; Liu M
Acta Neurol Belg; 2022 Dec; 122(6):1567-1573. PubMed ID: 35034333
[TBL] [Abstract][Full Text] [Related]
3. How common are ALS plateaus and reversals?
Bedlack RS; Vaughan T; Wicks P; Heywood J; Sinani E; Selsov R; Macklin EA; Schoenfeld D; Cudkowicz M; Sherman A
Neurology; 2016 Mar; 86(9):808-12. PubMed ID: 26658909
[TBL] [Abstract][Full Text] [Related]
4. Multipoint incremental motor unit number estimation versus amyotrophic lateral sclerosis functional rating scale and the medical research council sum score as an outcome measure in amyotrophic lateral sclerosis.
Jagtap SA; Kuruvilla A; Govind P; Nair MD; Sarada C; Varma RP
Ann Indian Acad Neurol; 2014 Jul; 17(3):336-9. PubMed ID: 25221407
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.
Johnson SA; Burke KM; Scheier ZA; Keegan MA; Clark AP; Chan J; Fournier CN; Berry JD
Muscle Nerve; 2022 Oct; 66(4):495-502. PubMed ID: 35904151
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of disease progression rate and related factors in amyotrophic lateral sclerosis patients at initial visit].
Zhang JH; Wang HF; Yang F; He ZQ; Feng F; Li M; Bai JM; Wang HR; Huang XS
Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(3):222-227. PubMed ID: 35042292
[No Abstract] [Full Text] [Related]
7. Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.
Young CA; Chaouch A; Mcdermott CJ; Al-Chalabi A; Chhetri SK; Talbot K; Malaspina A; Mills R; Tennant A
Amyotroph Lateral Scler Frontotemporal Degener; 2024 May; 25(3-4):400-409. PubMed ID: 38426231
[TBL] [Abstract][Full Text] [Related]
8. Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale.
Chew S; Burke KM; Collins E; Church R; Paganoni S; Nicholson K; Babu S; Scalia JB; De Marchi F; Ellrodt AL; Moura LMVR; Chan J; Berry JD
Amyotroph Lateral Scler Frontotemporal Degener; 2021 Nov; 22(7-8):467-477. PubMed ID: 33771057
[No Abstract] [Full Text] [Related]
9. Does the MUNIX Method Reflect Clinical Dysfunction in Amyotrophic Lateral Sclerosis: A Practical Experience.
Gawel M; Kuzma-Kozakiewicz M
Medicine (Baltimore); 2016 May; 95(19):e3647. PubMed ID: 27175687
[TBL] [Abstract][Full Text] [Related]
10. Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale.
Vasta R; Solero L; Palumbo F; Manera U; Torrieri MC; Grassano M; Canosa A; Moglia C; Calvo A; Chiò A
Amyotroph Lateral Scler Frontotemporal Degener; 2022 Aug; 23(5-6):383-389. PubMed ID: 34365891
[No Abstract] [Full Text] [Related]
11. Sensitivity and specificity of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised to detect dysarthria in individuals with amyotrophic lateral sclerosis.
Donohue C; Chapin JL; Anderson A; DiBiase L; Gray LT; Wymer JP; Plowman EK
Muscle Nerve; 2023 Sep; 68(3):296-302. PubMed ID: 37345346
[TBL] [Abstract][Full Text] [Related]
12. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients.
Park Y; Park J; Kim Y; Baek H; Kim SH
Nutrition; 2015; 31(11-12):1362-7. PubMed ID: 26429656
[TBL] [Abstract][Full Text] [Related]
13. Assessing upper limb function with ALSFRS-R in amyotrophic lateral sclerosis patients.
Pinto S; Gromicho M; de Carvalho M
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):445-448. PubMed ID: 31032642
[No Abstract] [Full Text] [Related]
14. Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R.
Fournier CN; James V; Glass JD
Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):311-316. PubMed ID: 36476010
[TBL] [Abstract][Full Text] [Related]
15. Use of a new ALS specific respiratory questionnaire: the ARES score.
Heiman-Patterson TD; Sherman MS; Yu D; Jackson CE; George A; Kasarskis EJ;
Amyotroph Lateral Scler Frontotemporal Degener; 2021; 22(sup1):48-53. PubMed ID: 34348538
[No Abstract] [Full Text] [Related]
16. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.
Mandrioli J; Biguzzi S; Guidi C; Sette E; Terlizzi E; Ravasio A; Casmiro M; Salvi F; Liguori R; Rizzi R; Pietrini V; Borghi A; Rinaldi R; Fini N; Chierici E; Santangelo M; Granieri E; Mussuto V; De Pasqua S; Georgoulopoulou E; Fasano A; ; Ferro S; D'Alessandro R
Neurol Sci; 2015 Dec; 36(12):2243-52. PubMed ID: 26205535
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
[TBL] [Abstract][Full Text] [Related]
18. Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
Shefner JM; Jacobsen B; Kupfer S; Malik FI; Meng L; Wei J; Wolff AA; Rudnicki SA
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):162-169. PubMed ID: 37641579
[TBL] [Abstract][Full Text] [Related]
19. Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.
Bakers JNE; de Jongh AD; Bunte TM; Kendall L; Han SS; Epstein N; Lavrov A; Beelen A; Visser-Meily JMA; van den Berg LH; van Eijk RPA
Amyotroph Lateral Scler Frontotemporal Degener; 2022 Nov; 23(7-8):500-507. PubMed ID: 34949141
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
